In VivoIn the top alliance by deal value, Pfizer entered into an exclusive global, ex-China, licensing agreement with 3SBio for the development, manufacturing, and commercialization of SSGJ-707, a bispecific
ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
Pink SheetThe European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including LIB Therapeutics’ lerodalcibep for treating primary hypercholesterolemia or
ScripPresident Donald Trump is repeating his threats of tariffs on the pharmaceutical industry and pressurizing companies to bring more manufacturing back to the US and while Ireland would be, on paper